Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...

Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...

Takeda revealed a handful of pipeline cuts in its fourth-quarter earnings results on Thursday, as the company focuses its ...

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

Los Angeles-based health system Cedars-Sinai is partnering with venture studio Redesign Health to build health tech startups ...

President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...

A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage.

Charles River Laboratories is set to start a strategic review and add four new board members after it settled on a ...